ZymeworksZYME
ZYME
About: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Employees: 286
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]
106% more call options, than puts
Call options by funds: $547K | Put options by funds: $266K
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
17% more capital invested
Capital invested by funds: $832M [Q3] → $973M (+$140M) [Q4]
6% more funds holding
Funds holding: 162 [Q3] → 171 (+9) [Q4]
3.03% more ownership
Funds ownership: 93.42% [Q3] → 96.45% (+3.03%) [Q4]
23% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 61
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
0%
upside
Avg. target
$21
59%
upside
High target
$30
131%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
LifeSci Capital | 131%upside $30 | Outperform Initiated | 11 Mar 2025 |
HC Wainwright & Co. Robert Burns 27% 1-year accuracy 46 / 173 met price target | 0%downside $13 | Neutral Maintained | 10 Mar 2025 |
Citigroup Yigal Nochomovitz 20% 1-year accuracy 8 / 41 met price target | 46%upside $19 | Buy Maintained | 7 Mar 2025 |
Financial journalist opinion
Based on 5 articles about ZYME published over the past 30 days
Positive
Seeking Alpha
2 days ago
Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline
Zymeworks is rated Strong Buy due to its improved outlook, FDA approval of Ziihera, advancing pipeline, and strong cash position. Zanidatamab (Ziihera) is a key asset with accelerated approval for HER2+ BTC and multiple ongoing trials in high-value indications. Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside potential for investors.
Positive
Seeking Alpha
2 days ago
Zymeworks: Poised For Growth With Platform Validation
Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3 million revenue in 2024 and a cash runway extending through late 2027. The robust pipeline includes zanidatamab for additional indications and promising early-stage candidates like ZW171 and ZW209 targeting high-unmet need cancers.
Neutral
GlobeNewsWire
5 days ago
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of six posters with new preclinical data from its preclinical, development-stage, and clinical programs at the American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, IL. “The breadth of data shared at AACR highlights the strength of our oncology portfolio across antibody-drug conjugates and T cell engagers, and demonstrates the novel approaches we employ using each modality,” said Paul Moore, Ph.D.
Neutral
GlobeNewsWire
1 week ago
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023, will continue as Executive Vice President & Chief Medical Officer, with primary responsibility for Zymeworks' emerging R&D portfolio in autoimmune and inflammatory disease and Global Clincal Development Operations. Ms. Barbara Schaeffler, who joined Zymeworks in 2024, has been promoted to Senior Vice President, Clinical Development Operations, reporting to Dr. Smith.
Neutral
GlobeNewsWire
1 week ago
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time.
Neutral
24/7 Wall Street
1 month ago
Insiders Make Huge Purchases of These 4 Biotech Stocks
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Neutral
GlobeNewsWire
1 month ago
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
1 month ago
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile
Positive
24/7 Wall Street
1 month ago
Huge Insider Buying: Victoria's Secret, Carl Icahn, and More
Despite (or perhaps because of) the volatility in the stock market and uncertainty about the economy, insiders are still scooping up shares of certain stocks.
Neutral
Zacks Investment Research
1 month ago
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?
Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Charts implemented using Lightweight Charts™